News | Radiopharmaceuticals and Tracers | September 03, 2015

Navidea Awarded $1.8M Grant for Manocept Agent Evaluation in Kaposi’s Sarcoma

Grant will cover preclinical safety trial and clinical trial evaluating detection of KS lesions with SPECT imaging

Navidea, SBIR grant, NCI, NIH, Kaposi's sarcoma, Tc99m tilmanocept, SPECT

Image courtesy of Navidea Biopharmaceuticals Inc.

September 3, 2015 — Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product. This will be followed by a clinical study of the safety and efficacy of single photon emission computed tomography (SPECT) imaging studies to identify and quantify both skin- and organ-associated Kaposi’s Sarcoma (KS) lesions in human patients. 

The SBIR grant is awarded in two parts, with the potential for total grant money of up to $1.8 million over two-and-a-half years. The first six-month funding segment of $300,000, which has already been awarded, is expected to enable Navidea to secure necessary collaborations and Institutional Review Board (IRB) approvals. The second funding segment could provide for up to an additional $1.5 million to accrue participants, perform the Phase 1/2 study, and perform data analyses to confirm the safety and effectiveness of intravenously administered Tc99m tilmanocept.

“Building on earlier research showing KS tumor cells abundantly express CD206, the tilmanocept receptor, and successful imaging with subcutaneous injection, we plan to evaluate intravenous administration of this targeted imaging agent to noninvasively locate internal KS lesions, which are currently challenging to identify and monitor,” commented Toby Maurer, M.D., FAAD, professor of dermatology at the University of California, San Francisco (UCSF), and chief of dermatology at San Francisco General Hospital and Trauma Center, who is co-PI at UCSF with Michael S. McGrath, M.D., PhD. “If successful, future diagnostic and eventually therapeutic developments have the potential to dramatically improve life expectancies and quality of life for patients suffering from Kaposi’s sarcoma.”

For more information: www.navidea.com

Related Content

Nuclear Cardiology Optimistic About Return to Pre-COVID-19 Exam Levels. An American Society of Nuclear Cardiology (ASNC) member survey are confident nuclear cardiology volumes will return to pre-pandemic levels. #COVID19 #SARScov2
News | Nuclear Imaging | June 01, 2020
June 1, 2020 — While acknowledging the challenges their specialty is facing, more than two-thirds of respondents to a
The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and is now the SNMMI 2020 Annual Meeting — Virtual Edition
News | Coronavirus (COVID-19) | April 30, 2020
April 30, 2020 — The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Army Spc. Jonathon Hyde and Spc. Casymn Harrison from the 1434th Engineer Company, Grayling, Mich., Michigan National Guard, prepare patient rooms at TCF Regional Care Center in Detroit in advance of receiving COVID-19 patients, April 9, 2020 #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

U.S. Army Spc. Jonathon Hyde and Spc. Casymn Harrison from the 1434th Engineer Company, Grayling, Mich., Michigan National Guard, prepare patient rooms at TCF Regional Care Center in Detroit in advance of receiving COVID-19 patients, April 9, 2020. The TCF Center in Detroit has been converted into a 970-bed alternative care facility for COVID-19 patients by the Federal Emergency Management Agency, in partnership with the U.S. Army Corps of Engineers and Michigan National Guard. (Photo courtesy of U.S. Air National Guard photo by Master Sgt. Scott Thompson)

Feature | Coronavirus (COVID-19) | April 15, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group.

Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group. Image courtesy of Eric Berg, University of California, Davis, CA

News | PET Imaging | April 10, 2020
April 10, 2020 — Combining 89Zr-labeled antibodies with total-body...
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
MR Solutions’ dry magnet MRI system for molecular imaging on display at EMIM 2020
News | Magnetic Resonance Imaging (MRI) | February 28, 2020
February 28, 2020 — MR Solutions will be displaying its la